Mohammed Rassool to Male
This is a "connection" page, showing publications Mohammed Rassool has written about Male.
Connection Strength
0,293
-
24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: an economic evaluation. Lancet Glob Health. 2025 Feb; 13(2):e355-e363.
Score: 0,027
-
Long-term efficacy and safety of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): extended follow-up of an open-label, multicentre, randomised, non-inferiority trial. Lancet Respir Med. 2024 Dec; 12(12):975-987.
Score: 0,026
-
Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial. Lancet Infect Dis. 2024 Sep; 24(9):1003-1014.
Score: 0,025
-
The lived experiences of tuberculosis survivors during the COVID-19 pandemic and government lockdown in South Africa: a qualitative analysis. BMC Public Health. 2023 09 05; 23(1):1729.
Score: 0,024
-
Efficacy, safety and central nervous system effects after switch from efavirenz/tenofovir/emtricitabine to doravirine/tenofovir/lamivudine. AIDS. 2021 04 01; 35(5):759-767.
Score: 0,020
-
Adjunctive host-directed therapies for pulmonary tuberculosis: a prospective, open-label, phase 2, randomised controlled trial. Lancet Respir Med. 2021 08; 9(8):897-908.
Score: 0,020
-
Raltegravir 1200 mg Once Daily vs 400 mg Twice Daily, With Emtricitabine and Tenofovir Disoproxil Fumarate, for Previously Untreated HIV-1 Infection: Week 96 Results From ONCEMRK, a Randomized, Double-Blind, Noninferiority Trial. J Acquir Immune Defic Syndr. 2018 08 15; 78(5):589-598.
Score: 0,017
-
Risk factors for early mortality on antiretroviral therapy in advanced HIV-infected adults. AIDS. 2017 10 23; 31(16):2217-2225.
Score: 0,016
-
Raltegravir 1200 mg once daily versus raltegravir 400 mg twice daily, with tenofovir disoproxil fumarate and emtricitabine, for previously untreated HIV-1 infection: a randomised, double-blind, parallel-group, phase 3, non-inferiority trial. Lancet HIV. 2017 11; 4(11):e486-e494.
Score: 0,016
-
Impact of early versus deferred antiretroviral therapy on estimated glomerular filtration rate in HIV-positive individuals in the START trial. Int J Antimicrob Agents. 2017 Sep; 50(3):453-460.
Score: 0,016
-
Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial. Lancet HIV. 2016 12; 3(12):e561-e568.
Score: 0,015
-
Antiretroviral therapy in HIV-1-infected individuals with CD4 count below 100 cells/mm3 results in differential recovery of monocyte activation. J Leukoc Biol. 2016 07; 100(1):223-31.
Score: 0,014
-
Pretreatment HIV Drug Resistance and HIV-1 Subtype C Are Independently Associated With Virologic Failure: Results From the Multinational PEARLS (ACTG A5175) Clinical Trial. Clin Infect Dis. 2015 May 15; 60(10):1541-9.
Score: 0,013
-
A randomized clinical trial comparing metabolic parameters after 48 weeks of standard- and low-dose stavudine therapy and tenofovir disoproxil fumarate therapy in HIV-infected South African patients. HIV Med. 2014 Jan; 15(1):3-12.
Score: 0,012
-
Prevalence of peripheral neuropathy in antiretroviral therapy naïve HIV-positive patients and the impact on treatment outcomes--a retrospective study from a large urban cohort in Johannesburg, South Africa. J Neurovirol. 2012 Jun; 18(3):162-71.
Score: 0,011
-
Initiating patients on antiretroviral therapy at CD4 cell counts above 200 cells/microl is associated with improved treatment outcomes in South Africa. AIDS. 2010 Aug 24; 24(13):2041-50.
Score: 0,010
-
Nurse versus doctor management of HIV-infected patients receiving antiretroviral therapy (CIPRA-SA): a randomised non-inferiority trial. Lancet. 2010 Jul 03; 376(9734):33-40.
Score: 0,010